白云山子公司获药品生产许可证，委托生产多款药品
财中社11月5日电白云山（600332/00874）发布关于子公司《药品生产许可证》变更的公告。子公司奇星药业近期获得广东省药品监督管理局核准的《药品生产许可证》，允许其委托中一药业生产多种药品，包括蛇胆川贝散、喉康散和复方余甘子利咽含片，同时也委托白云山制药总厂生产健脾补血颗粒。委托生产的有效期为3年，生产地址覆盖多个区域。
此次变更有助于公司优化资源配置，维持稳定的生产能力，以满足市场需求。公告指出，此次获得的《药品生产许可证》对公司的当期业绩没有重大影响。虽然医药行业存在市场环境变化等不确定性，但公司将继续关注生产和销售的动态。
2024年前三季度，白云山实现收入590.60亿元，归母净利润31.59亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10